Epidemiology and Natural History of Inflammatory Bowel Diseases, Gastroenterology, vol.140, issue.6, pp.1785-1794, 2011. ,
DOI : 10.1053/j.gastro.2011.01.055
URL : https://hal.archives-ouvertes.fr/hal-00631553
Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences, Gastroenterol, vol.126, issue.6, pp.1504-1517, 2004. ,
The gut microbiota in IBD, Nature Reviews Gastroenterology & Hepatology, vol.252, issue.10, pp.599-608, 2012. ,
DOI : 10.1038/nrgastro.2012.152
Colectomy rate in acute severe ulcerative colitis in the infliximab era, Digestive and Liver Disease, vol.40, issue.10, pp.821-827, 2008. ,
DOI : 10.1016/j.dld.2008.03.014
Risk of Colorectal Cancer in Patients With Ulcerative Colitis: A Meta-analysis of Population-Based Cohort Studies, Clinical Gastroenterology and Hepatology, vol.10, issue.6, pp.639-684, 2012. ,
DOI : 10.1016/j.cgh.2012.01.010
Chronic ulcerative colitis and colorectal cancer, Cancer Letters, vol.345, issue.2, p.2013 ,
DOI : 10.1016/j.canlet.2013.07.032
Azathioprine and 6 -mercaptopurine for maintenance of remission in ulcerative colitis, Cochrane Database Syst Rev, vol.9, p.10, 2012. ,
Methotrexate for induction of remission in ulcerative colitis, Cochrane Database Syst Rev, 2007. ,
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis, New England Journal of Medicine, vol.353, issue.23, pp.2462-76, 2005. ,
DOI : 10.1056/NEJMoa050516
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis, Gastroenterology, vol.142, issue.2, pp.257-65, 2012. ,
DOI : 10.1053/j.gastro.2011.10.032
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial, The Lancet, vol.380, issue.9857, pp.1909-1924, 2012. ,
DOI : 10.1016/S0140-6736(12)61084-8
URL : https://hal.archives-ouvertes.fr/hal-00742308
A Systematic Prospective Comparison of Noninvasive Disease Activity Indices in Ulcerative Colitis, Clinical Gastroenterology and Hepatology, vol.7, issue.10, pp.1081-1089, 2009. ,
DOI : 10.1016/j.cgh.2009.06.024
VALIDITY OF ACTIVITY INDICES IN ULCERATIVE COLITIS: COMPARISON OF CLINICAL AND ENDOSCOPIC INDICES, Digestive Endoscopy, vol.5, issue.1, pp.39-44, 2010. ,
DOI : 10.1111/j.1443-1661.2009.00916.x
Cortisone in Ulcerative Colitis, BMJ, vol.2, issue.4947, pp.1041-1049, 1955. ,
DOI : 10.1136/bmj.2.4947.1041
Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy, New England Journal of Medicine, vol.330, issue.26, pp.1841-1846, 1994. ,
DOI : 10.1056/NEJM199406303302601
Biological markers in inflammatory bowel disease: Practical consideration for clinicians, Gastroent??rologie Clinique et Biologique, vol.33, pp.158-73, 2009. ,
DOI : 10.1016/S0399-8320(09)73151-3
Biomarkers in inflammatory bowel disease: current practices and recent advances, Translational Research, vol.159, issue.4, pp.313-338, 2012. ,
DOI : 10.1016/j.trsl.2012.01.001
Correlation of C-Reactive Protein With Clinical, Endoscopic, Histologic, and Radiographic Activity in Inflammatory Bowel Disease, Inflammatory Bowel Diseases, vol.11, issue.8, pp.707-719, 2005. ,
DOI : 10.1097/01.MIB.0000173271.18319.53
C-reactive protein (CRP), erythrocyte sedimentation rate (ESR) or both? A systematic evaluation in pediatric ulcerative colitis, Journal of Crohn's and Colitis, vol.5, issue.5, pp.423-432, 2011. ,
DOI : 10.1016/j.crohns.2011.05.003
C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study, Gut, vol.57, issue.11, pp.1518-1541, 2008. ,
DOI : 10.1136/gut.2007.146357
Biological and histological parameters as predictors of relapse in ulcerative colitis: A prospective study, Saudi Journal of Gastroenterology, vol.17, issue.3, pp.194-202, 2011. ,
DOI : 10.4103/1319-3767.80383
C-reactive protein: a critical update, Journal of Clinical Investigation, vol.111, issue.12, pp.1805-1817, 2003. ,
DOI : 10.1172/JCI200318921
Role of biomarkers in the diagnosis of inflammatory bowel disease, Expert Opinion on Medical Diagnostics, vol.91, issue.4, pp.481-489, 2007. ,
DOI : 10.1136/gut.2006.113431
Reliability and Initial Validation of the Ulcerative Colitis Endoscopic Index of Severity, Gastroenterology, vol.145, issue.5, pp.16-5085, 2013. ,
DOI : 10.1053/j.gastro.2013.07.024
Complications of coloscopy, Acta Endoscopica, vol.27, issue.3, pp.195-203, 2000. ,
DOI : 10.1007/BF03022109
Colonoscopic perforations: a review of 30,366 patients, Surgical Endoscopy, vol.13, issue.6, pp.994-1001, 2007. ,
DOI : 10.1007/s00464-007-9251-7
S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules, Journal of Leukocyte Biology, vol.81, issue.1, pp.28-37, 2007. ,
DOI : 10.1189/jlb.0306170
La lactoferrine??: une prot??ine multifonctionnelle, m??decine/sciences, vol.25, issue.4, pp.361-370, 2009. ,
DOI : 10.1051/medsci/2009254361
Lactoferrin a multiple bioactive protein: An overview, Biochimica et Biophysica Acta (BBA) - General Subjects, vol.1820, issue.3, pp.226-262, 2012. ,
DOI : 10.1016/j.bbagen.2011.06.018
The antimicrobial activity of lactoferrin: Current status and perspectives, BioMetals, vol.17, issue.3 ,
DOI : 10.1023/B:BIOM.0000027691.86757.e2
Human pyruvate kinase M2: A multifunctional protein, Protein Science, vol.217, issue.Part 4, pp.2031-2075, 2010. ,
DOI : 10.1002/pro.505
Monocyte -derived dendritic cells release neopterin, J Leukoc Biol, vol.72, issue.6, pp.1148-53, 2002. ,
Zonulin and Its Regulation of Intestinal Barrier Function: The Biological Door to Inflammation, Autoimmunity, and Cancer, Physiological Reviews, vol.91, issue.1, pp.151-75, 2011. ,
DOI : 10.1152/physrev.00003.2008
Identification of human zonulin, a physiological modulator of tight junctions, as prehaptoglobin-2, Proceedings of the National Academy of Sciences, vol.106, issue.39, pp.16799-804, 2009. ,
DOI : 10.1073/pnas.0906773106
Role of faecal calprotectin as non-invasive marker of intestinal inflammation, Digestive and Liver Disease, vol.35, issue.9, pp.642-649, 2003. ,
DOI : 10.1016/S1590-8658(03)00381-5
Noninvasive Markers in the Assessment of Intestinal Inflammation in Inflammatory Bowel Diseases: Performance of Fecal Lactoferrin, Calprotectin, and PMN-Elastase, CRP, and Clinical Indices, The American Journal of Gastroenterology, vol.48, issue.1, 2007. ,
DOI : 10.1111/j.1572-0241.2007.01556.x
Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis, BMJ, vol.341, issue.jul15 1, p.3369, 2010. ,
DOI : 10.1136/bmj.c3369
Ruling out IBD: Estimation of the possible economic effects of pre-endoscopic screening with F-calprotectin, Clinical Biochemistry, vol.45, issue.7-8, pp.7-8552, 2012. ,
DOI : 10.1016/j.clinbiochem.2011.10.015
Fecal M2-pyruvate kinase (M2-PK): A novel marker of intestinal inflammation, Inflammatory Bowel Diseases, vol.13, issue.11, pp.1374-1382, 2007. ,
DOI : 10.1002/ibd.20214
Fecal dimeric M2-pyruvate kinase (tumor M2-PK) in the differential diagnosis of functional and organic bowel disorders, Inflammatory Bowel Diseases, vol.15, issue.11, pp.1630-1634, 2009. ,
DOI : 10.1002/ibd.20946
Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes, BMC Research Notes, vol.2, issue.1, p.221, 2009. ,
DOI : 10.1186/1756-0500-2-221
Fecal Calprotectin Correlates More Closely With the Simple Endoscopic Score for Crohn's Disease (SES-CD) than CRP, Blood Leukocytes, and the CDAI, The American Journal of Gastroenterology, vol.77, issue.1, pp.162-171, 2010. ,
DOI : 10.1038/ajg.2009.545
Fecal pyruvate kinase: A potential new marker for intestinal inflammation in children with inflammatory bowel disease, Scandinavian Journal of Gastroenterology, vol.49, issue.10, pp.1147-50, 2007. ,
DOI : 10.1097/00005176-199105000-00005
Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease, Przegl Lek, vol.67, issue.12, pp.1262-1267, 2010. ,
Neopterin Is a Novel Reliable Fecal Marker as Accurate as Calprotectin for Predicting Endoscopic Disease Activity in Patients with Inflammatory Bowel Diseases, Inflammatory Bowel Diseases, vol.19, issue.5, pp.1043-52, 2013. ,
DOI : 10.1097/MIB.0b013e3182807577
Neopterin Concentration as an Index of Disease Activity in Crohn???s Disease and Ulcerative Colitis, Journal of Clinical Gastroenterology, vol.47, issue.3, pp.246-51, 2013. ,
DOI : 10.1097/MCG.0b013e3182582cdb
Fecal calprotectin and lactoferrin for the prediction of inflammatory bowel disease relapse, Inflammatory Bowel Diseases, vol.15, issue.8 ,
DOI : 10.1002/ibd.20933
Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease, Gastroenterology, vol.119, issue.1, pp.15-22, 2000. ,
DOI : 10.1053/gast.2000.8523
Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis? (1) Journal of Crohn's & colitis, pp.144-52, 2010. ,
Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease, Gut, vol.54, issue.3, pp.364-372, 2005. ,
DOI : 10.1136/gut.2004.043406
Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies, Inflammatory Bowel Diseases, vol.18, issue.10, pp.1894-1903, 2012. ,
DOI : 10.1002/ibd.22861
Fecal Calprotectin Predicts the Clinical Course of Acute Severe Ulcerative Colitis, The American Journal of Gastroenterology, vol.55, issue.3, pp.673-681, 2009. ,
DOI : 10.1038/ajg.2008.119
Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels, World Journal of Gastroenterology, vol.17, issue.47, pp.5166-71, 2011. ,
DOI : 10.3748/wjg.v17.i47.5166
Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn??s disease, Inflammatory Bowel Diseases, vol.14, issue.10, pp.1392-1400, 2008. ,
DOI : 10.1002/ibd.20490
Fast and sharp decrease in calprotectin predicts remission by infliximab in anti-TNF na??ve patients with ulcerative colitis, Journal of Crohn's and Colitis, vol.6, issue.5, pp.557-62, 2012. ,
DOI : 10.1016/j.crohns.2011.11.002
Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNF?? blocking agents, Inflammatory Bowel Diseases, vol.18, issue.11, pp.2011-2018, 2012. ,
DOI : 10.1002/ibd.22863
Consecutive Fecal Calprotectin Measurements to Predict Relapse in Patients with Ulcerative Colitis Receiving Infliximab Maintenance Therapy, Inflammatory Bowel Diseases, vol.19, issue.10, pp.2111-2118, 2013. ,
DOI : 10.1097/MIB.0b013e31829b2a37
Discriminating IBD from IBS: Comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies, Inflammatory Bowel Diseases, vol.14, issue.1, pp.32-41, 2008. ,
DOI : 10.1002/ibd.20275
Fecal Markers: Calprotectin and Lactoferrin, Gastroenterology Clinics of North America, vol.41, issue.2, pp.483-95, 2012. ,
DOI : 10.1016/j.gtc.2012.01.007
Fecal lactoferrin as a noninvasive biomarker in inflammatory bowel diseases, Drugs of Today, vol.48, issue.2, pp.149-61, 2012. ,
DOI : 10.1358/dot.2012.48.2.1732555